CTOs on the Move

Patient-Centered Outcomes Research Institute

www.pcori.org

 
Patient-Centered Outcomes Research Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million
  • www.pcori.org
  • 1701 Pennsylvania Ave NW NW
    Washington, DC USA 20006
  • Phone: 202.683.6690

Executives

Name Title Contact Details
Rakesh Surve
Director, Information Security and Services Profile

Similar Companies

AIM Healthcare Services

To reduce the cost of healthcare and simplify healthcare information management.

InterGanics

InterGanics is a global solution-driven company that supports ingredients and finish products manufacturers to design an environmentally safe, socially responsible and economically sustainable sourcing strategy around Organic, Non-GMO and Specialty products.

Clinical Research Group

Clinical Research Group is a Villanova, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohana Pacific

Ohana Pacific Health is a locally owned & operated health care management company in Hawaii. We treat everyone and each other like family.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.